Ghosh A K, Rastogi A K
Curr Med Res Opin. 1981;7(7):482-7. doi: 10.1185/03007998109114288.
Thirty-two elderly patients with symptomatic osteoarthritis predominantly of the hip and/or knee joints were randomly treated on an open basis for 12 weeks with either 400 mg sulindac or 1200 mg ibuprofen per day. Clinical assessments were made before and after 1, 3, 6, 9 and 12 weeks of treatment, of disease activity, weight bearing pain, and pain on active and passive movement. Objective measurements were also made of duration of inactivity stiffness, knee flexion and hip abduction. The results showed that there was significant symptomatic improvement after treatment in the patients in both groups and that, apart from night pain, the differences between the groups in the subjective parameters at Week 12 were significant in favour of sulindac. Overall assessment of response to treatment also showed a significant preference for sulindac by patients and physician. Sulindac and ibuprofen were well-tolerated during the trial period, although 1 patient on sulindac had to be withdrawn because of a skin rash.
32例主要患有髋关节和/或膝关节症状性骨关节炎的老年患者,以开放试验方式随机接受治疗,为期12周,其中一组每天服用400毫克舒林酸,另一组每天服用1200毫克布洛芬。在治疗1、3、6、9和12周前后,对疾病活动度、负重疼痛以及主动和被动运动时的疼痛进行了临床评估。还对静止时僵硬的持续时间、膝关节屈曲和髋关节外展进行了客观测量。结果显示,两组患者治疗后症状均有显著改善,且除夜间疼痛外,第12周时两组主观参数的差异显著有利于舒林酸。对治疗反应的总体评估也显示,患者和医生对舒林酸有明显偏好。在试验期间,舒林酸和布洛芬耐受性良好,不过有1例服用舒林酸的患者因皮疹而退出试验。